Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

By afschroeder • March 14, 2026

Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez Madruga J, Liegeon G, Panchia R, Supparatpinyo K, Avihingsanon A, Creticos C, Swaminathan S, Doblecki-Lewis S, Rodriguez J, Siegel M, Oka S, Puthanakit T, Grinsztejn B, Sanders EJ, Lama JR, Lombaard J, Ndlovu N, Hwang P, Du J, Jackson B, Homony B, Evans B, Sklar P, Robertson MN, Plank RM. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093/cid/ciag171. Epub ahead of print. PMID: 41830344.

Tags: cisgender men, HIV-1 prevention, Infectious Diseases, islatravir, PrEP, Publications, Transgender women

DASC-LOT Framework and S3 Metric: A Novel Evaluation and Benchmarking Method to Assess Initiation, Duration, and Spectrum of Antimicrobial Usage at Inpatient Hospital Settings

Goto M, Imai S, Cho H, Merchant JA, Goetz MB, Perencevich EN, Alexander B, Shi Q, Holcombe A, Livorsi DJ. DASC-LOT Framework and S3 Metric:[...]

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions

Hermann JN, Kruger SE, Wodniak N, Holland J, Janosick V, Sanchez A, Zuniga-Moya JC, Brucker D, Torres B, Melo KM, Oliveros E, Kuran R, D'Assumpcao[...]

Structure and potential role of T6SS effector PdpC in Francisella tularensis intracellular lifestyle

Liu X, Clemens DL, Lee BY, Xia X, Fan H, Feng KY, Horwitz MA, Zhou ZH. Structure and potential role of T6SS effector PdpC in[...]